Ascentage Pharma Officially Included in Shenzhen-Hong Kong Stock Connect Program

SUZHOU,ChinaandROCKVILLE, Md., Dec. 30, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company was officially included into the Shenzhen-Hong Kong Stock Connect program(the "Hong Kong Stock Connect").